期刊文献+

冠心病合并糖耐量异常患者药物洗脱支架术后冠脉再狭窄危险因素的COX模型分析 被引量:5

原文传递
导出
摘要 目的 应用COX模型分析冠心病(CHD)合并糖耐量异常(IGT)患者接受药物洗脱支架(DES)术后再狭窄的危险因素.方法 选择124例接受DES治疗的CHD合并IGT患者,根据是否术后再狭窄分为:研究组52例,术后6个月内发生再狭窄;对照组72例,术后6个月内未发生再狭窄.比较两组年龄、吸烟史、家族史、体质量指数、糖化血红蛋白(HbA1c)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、平均动脉压(MAP)、病变部位、病变数目、术前狭窄程度、术后残余狭窄、支架长度、支架直径及球囊扩张压力值等因素的差异.应用COX比例风险模型分析DES术后再狭窄可能产生影响的15个特征性因素.结果 与对照组相比,研究组的吸烟史、HbA1c、LDL-C、HDL-C、多支病变、术后残余狭窄及支架直径差异有统计学意义(P<0.05).吸烟史、HbA1c、LDL-C、HDL-C、多支病变、术后残余狭窄及支架直径与DES再狭窄发生相关(P<0.05);吸烟史、HbA1c、LDL-C、术后残余狭窄是再狭窄的危险因素(P<0.05),而HDL-C是再狭窄的保护因素(P<0.05).结论 CHD合并IGT患者DES再狭窄与吸烟、高血糖、血脂代谢紊乱及手术解除狭窄不佳有相关性.
出处 《中国医师杂志》 CAS 2015年第8期1230-1232,共3页 Journal of Chinese Physician
  • 相关文献

参考文献9

  • 1Vardi M,Burke DA,Bangalore S,et al. Long-term efficacy andsafety of Zotarolimus-eluting stent in patients with diabetes melli-tus: pooled 5-year results from the ENDEAVOR III and IV trials[J], Catheter Cardiovasc Interv,2013, 82(7) :1031-1038.
  • 2Tian F, Chen Y, Liu H, et al. Assessment of characteristics ofneointimal hyperplasia after drug-eluting stent implantation in pa-tients with diabetes mellitus : an optical coherence tomography a-naiysis [ J ]. Cardiology ,2014, 128( 1 ) : 34-40.
  • 3Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treat-ment for the prevention of bare-metal stent restenosis in diabeticpatients[ J]. J Am Coll Cardiol,2013, 61(16) :1679-1685.
  • 4Lee HW,Lee HC, Kim BW, et al. Effects of low dose pioglita-zone on restenosis and coronary atherosclerosis in diabetic patientsundergoing drug eluting stent implantation [ J ]. Yonsei Med J,2013,54(6):1313-1320.
  • 5DAscenzo F,Bollati M,Quadri G,et al. Appraising failure of surgicaland percutaneous revascularization: long term outcomes from an obser-vational registry[J]. Minerva Cardioangiol,2013,61 (6) :675-681.
  • 6D^Amico G, Fabris T, Mojoli M, et al. Impact of drug-elutingstent generation on patient- and stent-related adverse events of dia-betic patients treated by percutaneous coronary intervention [ J ].Minerva Cardioangiol,2014, 62( 1 ) :9-18.
  • 7Spadaccio C,Patti G,De Marco F,et al. Usefulness of preprocedur-al levels of advanced glycation end products to predict restenosis inpatients with controlled diabetes mellitus undergoing drug-elutingstent implantation for stable angina pectoris (from the ProspectiveARMYDA-AGEs Study) [J]. Am J Cardiol,2013,112( 1) :21-26.
  • 8Takagi T, Okura H, Kobayashi Y, et al. A prospective, multi-center, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes : POPPS ( Preven-tion of In-Stent Neointimal Proliferation by Pioglitazone Study)[J]. JACC Caidiovasc Interv, 2009,2(6) :524-531.
  • 9周伟,杜巍,辛军,陆军,黄虔,周建平,李伟阳,熊斌,谢锐文,叶志彬,袁金权.杂交技术应用于复杂冠心病治疗的实践体会(附14例报告)[J].中国医师杂志,2012,14(9):1214-1215. 被引量:2

二级参考文献9

共引文献1

同被引文献31

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部